NovoCure (NASDAQ:NVCR – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.42) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
NovoCure (NASDAQ:NVCR – Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.08. NovoCure had a negative net margin of 40.65% and a negative return on equity of 51.63%. The firm had revenue of $133.80 million during the quarter, compared to analyst estimates of $133.80 million. During the same quarter last year, the business earned ($0.36) EPS. The company’s revenue was up 4.2% compared to the same quarter last year. On average, analysts expect NovoCure to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
NovoCure Stock Down 4.4 %
NovoCure stock opened at $12.24 on Wednesday. The company has a debt-to-equity ratio of 1.57, a quick ratio of 5.56 and a current ratio of 5.78. NovoCure has a 52-week low of $10.87 and a 52-week high of $83.60. The firm has a 50 day moving average price of $14.29 and a two-hundred day moving average price of $13.88. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -6.28 and a beta of 0.42.
Insiders Place Their Bets
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $28.00 price objective (up previously from $25.00) on shares of NovoCure in a research note on Wednesday, April 10th. Evercore ISI lifted their price objective on shares of NovoCure from $14.00 to $15.00 and gave the company an “in-line” rating in a research note on Friday, February 23rd. JPMorgan Chase & Co. lifted their price objective on shares of NovoCure from $15.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, March 19th. Wedbush reissued a “neutral” rating and issued a $21.00 price target on shares of NovoCure in a research report on Wednesday, March 27th. Finally, Wells Fargo & Company reduced their price target on shares of NovoCure from $49.00 to $42.00 and set an “overweight” rating for the company in a research report on Wednesday, April 3rd. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.13.
Check Out Our Latest Stock Analysis on NovoCure
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
Read More
- Five stocks we like better than NovoCure
- 3 Tickers Leading a Meme Stock Revival
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What Are Trending Stocks? Trending Stocks Explained
- Hilton Demonstrates Asset Light is Right for Investors
- Profitably Trade Stocks at 52-Week Highs
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.